Are we undermining the value of palliative care through advanced cancer clinical trial consent language?
Commentary
Puja J. Umaretiya, Jennifer P. Rubin, Jennifer M. Snaman, Christina Ullrich, Angela M. Feraco, Veronica Dussel, Joanne Wolfe, Elisha Waldman
Cancer, 10 March 2021
Abstract
Informed consents for advanced cancer trials contain language that misrepresents palliative care as an alternative to trial participation. This language should be revised to highlight that palliative care is appropriate at any point in the illness trajectory and alongside disease‐directed therapy.
Are we undermining the value of palliative care through advanced cancer clinical trial consent language?
Center for Informed Consent Integrity 